136 related articles for article (PubMed ID: 8212155)
21. Trial of steroid withdrawal in renal transplant recipients with long-term--surviving allograft.
Mizuno Y; Kikuchi H; Fujimori K; Doi H; Orii T; Ohkohchi N; Satomi S
Transplant Proc; 2000 Nov; 32(7):1677-8. PubMed ID: 11119888
[No Abstract] [Full Text] [Related]
22. Are heart transplant recipients more likely to develop skin cancer than kidney transplant recipients?
Gjersvik P; Hansen S; Møller B; Leivestad T; Geiran O; Simonsen S; Pfeffer P; Fauchald P
Transpl Int; 2000; 13 Suppl 1():S380-1. PubMed ID: 11112037
[TBL] [Abstract][Full Text] [Related]
23. First report of an Australian randomised trial comparing cyclosporine+prednisolone with cyclosporine+azathioprine and cyclosporine+azathioprine+prednisolone in renal transplantation.
Hardie IR; Tiller DJ; Mahony JF; Miach PJ; Thomson NM; Thatcher GN; Rigby RJ; Menzies BL
Transplant Proc; 1992 Oct; 24(5):2241-2. PubMed ID: 1413040
[No Abstract] [Full Text] [Related]
24. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
Friemann S; Feuring E; Padberg W; Ernst W
Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
[No Abstract] [Full Text] [Related]
25. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients.
Cueto-Manzano AM; Konel S; Crowley V; France MW; Freemont AJ; Adams JE; Mawer B; Gokal R; Hutchison AJ
Transplantation; 2003 Jun; 75(12):2053-8. PubMed ID: 12829911
[TBL] [Abstract][Full Text] [Related]
26. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation.
Brown JH; Murphy BG; Douglas AF; Short CD; Bhatnagar D; Mackness MI; Hunt LP; Doherty CC; Durrington PN
Nephron; 1997; 75(3):277-82. PubMed ID: 9069448
[TBL] [Abstract][Full Text] [Related]
27. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients.
Flechner SM; Zhou L; Derweesh I; Mastroianni B; Savas K; Goldfarb D; Modlin CS; Krishnamurthi V; Novick A
Transplantation; 2003 Dec; 76(12):1729-34. PubMed ID: 14688524
[TBL] [Abstract][Full Text] [Related]
28. Everolimus versus azathioprine in a cyclosporine and ketoconazole-based immunosuppressive therapy in kidney transplant: 3-year follow-up of an open-label, prospective, cohort, comparative clinical trial.
Gonzalez F; Espinoza M; Herrera P; Rocca X; Reynolds E; Lorca E; Roessler E; Hidalgo J; Espinoza O
Transplant Proc; 2010; 42(1):270-2. PubMed ID: 20172327
[TBL] [Abstract][Full Text] [Related]
29. Five years' follow-up of renal glomerular and tubular functions in heart transplant recipients.
Hartmann A; Andereassen AK; Holdaas H; Simonsen S; Geiran O; Berg KJ
J Heart Lung Transplant; 1996 Oct; 15(10):972-9. PubMed ID: 8913913
[TBL] [Abstract][Full Text] [Related]
30. Control of cytomegalovirus disease in renal transplant patients treated with prednisone, azathioprine and cyclosporine using intensive monitoring and decreased immunosuppression.
Gómez E; de Oña M; Mélon S; Alvarez R; Laures A; Rodríguez M; Pobes A; Alvarez-Grande J
Nephron; 1999; 82(3):238-45. PubMed ID: 10395996
[TBL] [Abstract][Full Text] [Related]
31. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study.
Wong KM; Cheung CY; Chan YH; Chak WL; Choi KS; Chau KF; Li CS
Transplant Proc; 2000 Nov; 32(7):1721-2. PubMed ID: 11119907
[No Abstract] [Full Text] [Related]
32. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression.
Ratcliffe PJ; Dudley CR; Higgins RM; Firth JD; Smith B; Morris PJ
Lancet; 1996 Sep; 348(9028):643-8. PubMed ID: 8782754
[TBL] [Abstract][Full Text] [Related]
33. Analysis of risk factors for cutaneous warts in renal transplant recipients.
Barba A; Tessari G; Talamini G; Chieregato GC
Nephron; 1997; 77(4):422-6. PubMed ID: 9434064
[TBL] [Abstract][Full Text] [Related]
34. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy.
Bakker RC; Hollander AA; Mallat MJ; Bruijn JA; Paul LC; de Fijter JW
Kidney Int; 2003 Sep; 64(3):1027-34. PubMed ID: 12911553
[TBL] [Abstract][Full Text] [Related]
35. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
[TBL] [Abstract][Full Text] [Related]
36. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2003 Dec; 35(8):2940-2. PubMed ID: 14697944
[TBL] [Abstract][Full Text] [Related]
37. Gastric emptying time in renal transplant recipients treated with cyclosporine.
Ozkaya O; Derici U; Buyan N; Dalgic A; Dalgic B; Cingi E; Kitapci M; Sindel S; Hasanoglu E
Transplant Proc; 2003 Dec; 35(8):2927-30. PubMed ID: 14697940
[TBL] [Abstract][Full Text] [Related]
38. Oxidative stress in cyclosporin and azathioprine treated renal transplant patients.
McGrath LT; Treacy R; McClean E; Brown JH
Clin Chim Acta; 1997 Aug; 264(1):1-12. PubMed ID: 9267698
[TBL] [Abstract][Full Text] [Related]
39. Adrenal function as an index of the immunosuppressive activity of glucocorticoids (prednisolone) in renal allograft recipients.
Kozaki M; Hirano T; Oka K
Transplant Proc; 1987 Feb; 19(1 Pt 3):2237-9. PubMed ID: 3079076
[No Abstract] [Full Text] [Related]
40. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
